STUDY ON THE EFFECT OF INHALED CICLESONIDE ON SYSTEMIC INFLAMMATION IN BRONCHIAL ASTHMA

Introduction: The effect of Ciclesonide on systemic inflammatory and allergic markers such as C reactive protein (CRP) and IgE needs to be evaluated when given in therapeutic doses to patients of bronchial asthma.

Aims and Objectives: To evaluate effect of inhaled Ciclesonide on systemic inflammatory [CRP, Erythrocyte Sedimentation Rate (ESR)], allergic [Absolute Eosinophil Count (AEC), Sputum Eosinophil Count (SEC), IgE] in bronchial asthma.

Methods: The above parameters were assessed in 20 new patients of mild and moderate bronchial asthma who had not received inhaled or oral steroids during the past 3 months. Ciclesonide (160 mcg) was given once daily for 6weeks. All parameters were repeated at end of the study.

Results: CRP, AEC, SEC and ESR were seen to reduce significantly after treatment. Mean reduction in CRP was 2.86±0.91, p=0.011; SEC was 19.33±3.87, p=0.008, ESR was 5.35±0.79, p=0.029 and AEC was 98.95±6.24,p=0.006. IgE (202.05±15.64, p=0.060) showed non-significant reduction after treatment. FEV1 and FVC improved significantly after treatment. Mean increase in FEV1 was 0.35±0.40, p<0.01; and FVC was 0.36±0.31,p<0.01.

Conclusion: Inhaled Ciclesonide caused significant changes in systemic inflammatory parameters. Significant correlation was seen between AEC, SEC and CRP.